AstraZeneca Enters Two Agreements for Transthyretin Amyloid Cardiomyopathy and Transthyretin Amyloidosis
TeroVesalainen / Pixabay

AstraZeneca Enters Two Agreements for Transthyretin Amyloid Cardiomyopathy and Transthyretin Amyloidosis

AstraZeneca has entered into two collaborative agreements which will improve research for two rare diseases: transthyretin amyloid cardiomyopathy (ATTR-CM) and transthyretin amyloidosis (ATTR). N1006 The first collaboration is with Neurimmune…

Continue Reading AstraZeneca Enters Two Agreements for Transthyretin Amyloid Cardiomyopathy and Transthyretin Amyloidosis
Treatment for Pre-symptomatic Spinal Muscular Atrophy Patients Granted FDA Priority Review
source: pixabay.com

Treatment for Pre-symptomatic Spinal Muscular Atrophy Patients Granted FDA Priority Review

PTC Therapeutics Inc. has just announced that their supplemental new drug application for Evrysdi (risdiplam) has been given priority review by the FDA. The aim is to expand the indication…

Continue Reading Treatment for Pre-symptomatic Spinal Muscular Atrophy Patients Granted FDA Priority Review